# Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

> **NCT02186834** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 28 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Liposomal doxorubicin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02186834
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-23
- **Primary completion:** 2017-11-08
- **Final completion:** 2018-03-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02186834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02186834, "Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02186834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*